Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000947871-25-000384
Filing Date
2025-04-11
Accepted
2025-04-11 19:24:24
Documents
1
Period of Report
2025-04-09

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 8678
  Complete submission text file 0000947871-25-000384.txt   11512
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 4 | Act: 34 | File No.: 001-39696 | Film No.: 25833891

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 212-739-6400
OrbiMed Capital GP VI LLC (Reporting) CIK: 0001682115 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39696 | Film No.: 25833890

Mailing Address 80 GUEST STREET BOSTON MA 02135
Business Address 80 GUEST STREET BOSTON MA 02135 617-500-8099
Compass Therapeutics, Inc. (Issuer) CIK: 0001738021 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
OrbiMed Genesis GP LLC (Reporting) CIK: 0001808744 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39696 | Film No.: 25833889